Analysts Expect Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.21 Per Share
Wall Street brokerages expect Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) to post earnings of ($1.21) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Alder BioPharmaceuticals’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($1.98). Alder BioPharmaceuticals reported earnings per share of ($0.70) during the same quarter last year, which would indicate a negative year over year growth rate of 72.9%. The firm is scheduled to report its next earnings report on Thursday, October 26th.
On average, analysts expect that Alder BioPharmaceuticals will report full-year earnings of ($5.75) per share for the current fiscal year, with EPS estimates ranging from ($7.42) to ($4.82). For the next financial year, analysts forecast that the business will report earnings of ($4.00) per share, with EPS estimates ranging from ($6.85) to ($2.83). Zacks’ EPS calculations are an average based on a survey of analysts that cover Alder BioPharmaceuticals.
Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.67) by $0.19. The firm had revenue of $0.68 million for the quarter. During the same quarter last year, the business posted ($0.79) EPS. The firm’s revenue for the quarter was up 518.2% on a year-over-year basis.
ALDR has been the topic of a number of research analyst reports. Needham & Company LLC set a $36.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday, July 11th. Aegis reissued a “buy” rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, July 5th. Mizuho initiated coverage on shares of Alder BioPharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Credit Suisse Group set a $11.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 24th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.69.
Alder BioPharmaceuticals (NASDAQ ALDR) opened at 11.50 on Monday. The firm’s market capitalization is $778.70 million. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $34.30. The stock’s 50 day moving average is $11.22 and its 200-day moving average is $14.18.
In related news, insider Mark James Litton sold 16,520 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total transaction of $203,691.60. Following the completion of the transaction, the insider now owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.60% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC acquired a new stake in shares of Alder BioPharmaceuticals in the third quarter worth $132,000. Asymmetry Capital Management L.P. increased its position in shares of Alder BioPharmaceuticals by 320.1% in the second quarter. Asymmetry Capital Management L.P. now owns 166,752 shares of the biopharmaceutical company’s stock worth $1,909,000 after acquiring an additional 127,056 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Alder BioPharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 698 shares in the last quarter. Redmile Group LLC increased its position in shares of Alder BioPharmaceuticals by 16.4% in the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock worth $25,463,000 after acquiring an additional 313,925 shares in the last quarter. Finally, State Street Corp increased its position in shares of Alder BioPharmaceuticals by 9.4% in the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock worth $22,267,000 after acquiring an additional 167,642 shares in the last quarter. 76.16% of the stock is owned by institutional investors.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.